Group 1 - The core viewpoint is that Mingde Biological has experienced significant growth in market capitalization and development in the POCT rapid diagnostic field since its listing, but its operational performance has shown notable fluctuations in recent years [1][3]. - Mingde Biological's main business includes the independent research, production, and sales of POCT rapid diagnostic reagents and testing instruments, with in vitro diagnostic products and solutions accounting for the highest revenue share at 62.89% [3]. - The company achieved a cumulative profit growth of 21.33% from a net profit of 0.61 billion yuan in 2018 to 0.75 billion yuan in 2024, with no annual losses recorded since its listing [3]. Group 2 - Revenue analysis shows that Mingde Biological's revenue peaked at 9.59 billion yuan in 2020 but fell to 3.50 billion yuan in 2024, indicating a significant decline post-pandemic [3]. - Profit analysis reveals that the net profit reached a high of 4.69 billion yuan in 2020, dropping to 0.75 billion yuan in 2024, reflecting a substantial adjustment after the pandemic peak [3]. - Since its listing, Mingde Biological's market capitalization has increased by 142%, peaking at 150.45 billion yuan in May 2022, but has since decreased by 68.47% to 47.43 billion yuan as of July 2023 [5].

近期明德生物（002932）发布2024年年报，证券之星财报模型分析如下： 从单季度数据来看，第四季度营业总收入为1.24亿元，同比上升0.68%；归母净利润为-641.88万元，同 比上升90.88%；扣非净利润为-1.01亿元，同比上升40.45%。虽然第四季度营收略有增长，但扣非净利 润仍为负值，且全年整体表现不佳。 费用与利润率 经营概况 明德生物发布的2024年年报显示，公司全年营业总收入为3.5亿元，同比下降53.3%。归母净利润为 7451.96万元，同比下降0.54%。扣非净利润为-1.4亿元，同比下降12.74%。尽管归母净利润降幅较小， 但扣非净利润的大幅下滑表明公司主营业务盈利能力减弱。 单季度表现 总体来看，明德生物2024年的财务表现不尽如人意，主营收入和利润均出现不同程度的下滑，费用占比 上升明显。公司需进一步优化成本控制，提升主营业务盈利能力，以应对未来的市场挑战。 货币资金：4.94亿元，同比下降51.37% 应收账款：7.64亿元，同比下降36.79% 有息负债：729.63万元，同比下降76.39% 每股净资产：25.06元，同比下降3.31% 每股经营性现金流：-0.37 ...